Interleukin-17A (IL-17A): A silent amplifier of COVID-19

Maione, Francesco; Casillo, GIAN MARCO; Raucci, Federica; Cristian, Salvatore; Giovanna, Ambrosini; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria.

doi:10.1016/j.biopha.2021.111980

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.

Interleukin-17A (IL-17A): A silent amplifier of COVID-19 / Maione, Francesco; Casillo, GIAN MARCO; Raucci, Federica; Salvatore, Cristian; Ambrosini, Giovanna; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria.. - In: BIOMÉDECINE & PHARMACOTHÉRAPIE. - ISSN 0753-3322. - 142:(2021), p. 111980. [10.1016/j.biopha.2021.111980]